<DOC>
	<DOCNO>NCT00535119</DOCNO>
	<brief_summary>This phase I trial study side effect best dose veliparib give together carboplatin paclitaxel treat patient advance solid cancer . Veliparib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving veliparib together carboplatin paclitaxel may help kill tumor cell .</brief_summary>
	<brief_title>Veliparib , Carboplatin , Paclitaxel Treating Patients With Advanced Solid Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommend dose phase II study veliparib ( ABT-888 ) administer combination carboplatin paclitaxel patient advance solid malignancy . ( Stratum I ) II . To determine recommend dose phase II study veliparib administer combination carboplatin paclitaxel patient advance solid malignancy harbor germline BRCA1/2 mutation . ( Stratum II ) ( added 04/07/09 ) SECONDARY OBJECTIVES : I . To define dose-limiting toxicity toxicity associate use combination . II . To obtain preliminary evidence antitumor activity patient treat combination . III . To evaluate pharmacokinetic parameter veliparib , carboplatin , paclitaxel administer combination . IV . To conduct correlative science study . OUTLINE : This multicenter , dose-escalation study veliparib . Patients stratify accord BRCA status ( [ stratum I ] vs yes [ stratum II ] ) . Patients receive carboplatin intravenously ( IV ) 30 minute paclitaxel IV 3 hour day 3 veliparib orally ( PO ) twice daily day 1-7 recommend phase II dose determine . Treatment repeat every 3 week least 6 course absence disease progression unacceptable toxicity . Patients undergo peripheral blood mononuclear cell collection periodically pharmacokinetic biomarker study . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Hereditary Breast Ovarian Cancer Syndrome</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid malignancy Patients enrol stratum II study must BRCA1/2 mutation ( added 04/07/09 ) Patients CNS metastasis must stable therapy CNS metastasis ( surgery , radiotherapy stereotactic radiosurgery ) &gt; 3 month must steroid treatment prior study enrollment ECOG performance status 02 Life expectancy &gt; 12 week ANC ≥ 1,500/μL Platelet count ≥ 100,000/μL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) More 3 week since prior radiotherapy Prior veliparib allow Known history allergic reaction veliparib , carboplatin , Cremophorpaclitaxel Uncontrolled intercurrent illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude compliance study requirement Peripheral neuropathy &gt; grade 1 Inability take oral medication continuous basis Active seizure history seizure disorder Evidence bleeding diathesis Received &gt; 3 prior chemotherapy regimen advance stage disease patient enrol stratum I ( upper limit number prior regimens patient enrol stratum II ) ( added 04/07/09 ) Adjuvant chemotherapy administer ≥ 2 year prior enrollment study count prior chemotherapy regimen Other concurrent investigational agent Concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>